Treatment of Hepatitis B in Decompensated Liver Cirrhosis

Overview

Journal Int J Hepatol

Publisher Wiley

Specialty Gastroenterology

Date 2011 Oct 14

PMID 21994876

Citations 10

Authors

Richard Guan

Hock Foong Lui

Affiliations

Soon will be listed here.

Abstract

Chronic hepatitis B infection progresses from an asymptomatic persistently infected state to chronic hepatitis, cirrhosis, decompensated liver disease, and/or hepatocellular carcinoma. About 3% of patients with chronic hepatitis develop cirrhosis yearly, and about 5% of individuals with hepatitis B cirrhosis become decompensated annually. The outcome for patients with decompensated cirrhosis is bleak. Lamivudine, the first oral antiviral agent available for hepatitis B treatment is safe and effective and can improve or stabilize liver disease in patients with advanced cirrhosis and viraemia. Viral resistance restricts its prolonged use. Entecavir and tenofovir are newer agents with excellent resistance profile to date. These and some other antiviral agents are being investigated for optimal use in this rather challenging patient group.

Citing Articles

Recovery of cardiac electrophysiological alterations by heart rate complexity based on multiscale entropy following liver transplantation.

Shih P, Cheng Y, Ho S, Huang H, Yeh J, Sun W Sci Rep. 2024; 14(1):7467.

PMID: 38553611 PMC: 10980714. DOI: 10.1038/s41598-024-58191-8.

Identification of miR-4793-3p as a potential biomarker for bacterial infection in patients with hepatitis B virus-related liver cirrhosis: A pilot study.

Lin S, Lin M, Ma H, Wang X, Zhang D, Wu W Exp Ther Med. 2020; 21(2):120.

PMID: 33335583 PMC: 7739867. DOI: 10.3892/etm.2020.9552.

Role of alcohol in pathogenesis of hepatitis B virus infection.

Ganesan M, Eikenberry A, Poluektova L, Kharbanda K, Osna N World J Gastroenterol. 2020; 26(9):883-903.

PMID: 32206001 PMC: 7081008. DOI: 10.3748/wjg.v26.i9.883.

Hayward K, Patel P, Valery P, Horsfall L, Li C, Wright P Hepatol Commun. 2019; 3(5):620-631.

PMID: 31061951 PMC: 6492469. DOI: 10.1002/hep4.1334.

Prognostic significance of vitamin D receptor (VDR) gene polymorphisms in liver cirrhosis.

Triantos C, Aggeletopoulou I, Kalafateli M, Spantidea P, Vourli G, Diamantopoulou G Sci Rep. 2018; 8(1):14065.

PMID: 30218108 PMC: 6138740. DOI: 10.1038/s41598-018-32482-3.

References

Kapoor D, Guptan R, Wakil S, Kazim S, Kaul R, Agarwal S . Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2000; 33(2):308-12. DOI: 10.1016/s0168-8278(00)80372-4. View

Dienstag J, Schiff E, Wright T, Perrillo R, Hann H, Goodman Z . Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999; 341(17):1256-63. DOI: 10.1056/NEJM199910213411702. View

Tandon P, Garcia-Tsao G . Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008; 28(1):26-42. DOI: 10.1055/s-2008-1040319. View

Chen D . Natural history of chronic hepatitis B virus infection: new light on an old story. J Gastroenterol Hepatol. 1993; 8(5):470-5. DOI: 10.1111/j.1440-1746.1993.tb01551.x. View

Lai C, Chien R, Leung N, Chang T, Guan R, Tai D . A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998; 339(2):61-8. DOI: 10.1056/NEJM199807093390201. View

Keeffe E . Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases?. Am J Gastroenterol. 1995; 90(2):201-5. View

Hui A, Chan H, Leung N, Hung L, Chan F, Jao-Yiu Sung J . Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. J Clin Gastroenterol. 2002; 34(5):569-72. DOI: 10.1097/00004836-200205000-00018. View

Benvegnu L, Fattovich G, Noventa F, Tremolada F, Chemello L, Cecchetto A . Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer. 1994; 74(9):2442-8. DOI: 10.1002/1097-0142(19941101)74:9<2442::aid-cncr2820740909>3.0.co;2-#. View

Gines P, Cardenas A . The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis. 2008; 28(1):43-58. DOI: 10.1055/s-2008-1040320. View

10.

Fattovich G, Brollo L, GIUSTINA G, Noventa F, Pontisso P, Alberti A . Natural history and prognostic factors for chronic hepatitis type B. Gut. 1991; 32(3):294-8. PMC: 1378837. DOI: 10.1136/gut.32.3.294. View

11.

Chu C, Liaw Y . Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis. 2006; 26(2):142-52. DOI: 10.1055/s-2006-939752. View

12.

Okazaki I, Maruyama K, Funatsu K, Kashiwazaki K, Tsuchiya M . Ten year survival rate of 131 patients with liver cirrhosis excluded the association of liver carcinoma at the establishment of diagnosis. Gastroenterol Jpn. 1980; 15(4):350-4. DOI: 10.1007/BF02774306. View

13.

. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1996; 45(RR-15):1-30. View

14.

Lange C, Bojunga J, Hofmann W, Wunder K, Mihm U, Zeuzem S . Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009; 50(6):2001-6. DOI: 10.1002/hep.23346. View

15.

Wong D, Cheung A, ORourke K, Naylor C, Detsky A, Heathcote J . Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993; 119(4):312-23. DOI: 10.7326/0003-4819-119-4-199308150-00011. View

16.

Hadziyannis S, Tassopoulos N, Heathcote E, Chang T, Kitis G, Rizzetto M . Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006; 131(6):1743-51. DOI: 10.1053/j.gastro.2006.09.020. View

17.

Lok A, McMahon B . Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3):661-2. DOI: 10.1002/hep.23190. View

18.

Kamath P, Wiesner R, Malinchoc M, Kremers W, Therneau T, Kosberg C . A model to predict survival in patients with end-stage liver disease. Hepatology. 2001; 33(2):464-70. DOI: 10.1053/jhep.2001.22172. View

19.

James J . Tenofovir approved: broad indication. AIDS Treat News. 2002; (373):2-3. View

20.

Chang T, Gish R, de Man R, Gadano A, Sollano J, Chao Y . A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006; 354(10):1001-10. DOI: 10.1056/NEJMoa051285. View